Results 11 to 20 of about 1,669 (70)
Frontiers in Aging Neuroscience, 2021 BackgroundIt remains unclear why patients with young-onset Parkinson’s disease more often develop levo-dihydroxyphenylalanine (L-dopa)-induced dyskinesia (LID) and have a more severe form than patients with old-onset Parkinson’s disease. Previous studies
Haruo Nishijima +8 more
doaj +1 more source
Crop Journal, 2018 Faba bean (Vicia faba L.) has been identified as a rich source of l-DOPA, which is used in treating Parkinson's disease. Biosynthesis and accumulation of active substances such as l-DOPA in plant tissues may interact with growing conditions and ...
Fatemeh Etemadi +4 more
doaj +1 more source
Striatal astrocytes act as a reservoir for L-DOPA.
PLoS ONE, 2014 L-DOPA is therapeutically efficacious in patients with Parkinson's disease (PD), although dopamine (DA) neurons are severely degenerated. Since cortical astrocytes express neutral amino acid transporter (LAT) and DA transporter (DAT), the uptake and ...
Masato Asanuma +4 more
doaj +1 more source
Cells, 2023 Dopamine replacement therapy for Parkinson’s disease is achieved using L-DOPA or dopamine D2/3 agonists, such as ropinirole. Here, we compare the effects of L-DOPA and ropinirole, alone or in combination, on patterns of glial and microvascular reactivity
Osama F. Elabi +4 more
doaj +1 more source
Neurobiology of Disease, 2011 The therapeutic benefit of L-DOPA is commonly attributed to restoration of dopamine (DA) extracellular levels in the striatum of Parkinsonian patients. However, the loss of efficacy of L-DOPA after chronic use is paradoxically associated with a similar ...
Sylvia Navailles +3 more
doaj +1 more source
Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity
Frontiers in Molecular Neuroscience, 2018 Until now, the dopamine (DA) precursor, L-3,4-dihydroxyphenylalanine (L-DOPA), remains the gold standard effective drug therapy for Parkinson’s disease (PD) patients.
Di-Sheng Lu +7 more
doaj +1 more source
Frontiers in Behavioral Neuroscience, 2014 Bradykinesia (slowness of movement) and other characteristic motor manifestations of Parkinson’s disease (PD) are alleviated by treatment with L-dihydroxyphenylalanine (L-DOPA).
Stefania eSgroi +3 more
doaj +1 more source
Evidence of
Journal of Biomedical Science, 2010 Background l-Dopa has been used for Parkinson's disease management for a long time. However, its wide variety in the rate and the extent of absorption remained challenge in designing suitable therapeutic regime.
Wang Chun-Li +5 more
doaj +1 more source
Neurobiology of Disease, 2010 Benefit and motor side effects of l-DOPA in Parkinson's disease have been related to dopamine transmission in the striatum. However, the putative involvement of serotonergic neurons in the dopaminergic effects of l-DOPA suggests that the striatum is not ...
Sylvia Navailles +3 more
doaj +1 more source
Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure. [PDF]
PLoS ONE, 2008 L-3,4-dihydroxypheylalanine (L-dopa)-induced dyskinesia represent a debilitating complication of therapy for Parkinson's disease (PD) that result from a progressive sensitization through repeated L-dopa exposures. The MPTP macaque model was used to study
Birger Scholz +11 more
doaj +1 more source